亚太药业：上半年净利润同比增长1821%

Core Viewpoint - The company reported a significant decline in revenue while achieving a remarkable increase in net profit due to asset disposal [1] Financial Performance - The company achieved an operating revenue of 152 million yuan in the first half of the year, representing a year-on-year decrease of 31.48% [1] - The net profit attributable to shareholders was 105 million yuan, showing a year-on-year increase of 1820.97% [1] Asset Disposal - The report period included a non-current asset disposal gain of 149 million yuan, primarily from the sale of 100% equity in its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd. [1]